License Agreement (Details Narrative) - License Agreement [Member]	Aug. 23, 2020 shares
Description of milestones	Company will issue shares of common stock to 7 to Stand upon completion of the following milestones: ● Common shares representing 5% of total number of outstanding common shares of the Company immediately following any change of control of the Company; ● Common shares representing 5% of total number of outstanding common shares of the Company immediately following the first round of funding under a private offer of equity or debt securities; ● Common shares representing 5% of total number of outstanding common shares of the Company immediately following the first round of funding under a private offer of equity or debt securities; ● Common shares representing 5% of total number of outstanding common shares of the Company immediately following the commencement of clinical trials for Federal Drug Administration clearance of the product; and ● Common shares representing an adjustment to increase 7 to Stand’s total ownership to 19.99% of total number of outstanding common shares of the Company immediately following FDA clearance of the product for sale.
Patents [Member]
Royalty of net sales	7.10%
Patents [Member] \| Fabrizio de Silvestri [Member]
Rights to issued	10,610,592

Company will issue shares of common stock to 7 to Stand upon completion of the following milestones: ● Common shares representing 5% of total number of outstanding common shares of the Company immediately following any change of control of the Company; ● Common shares representing 5% of total number of outstanding common shares of the Company immediately following the first round of funding under a private offer of equity or debt securities; ● Common shares representing 5% of total number of outstanding common shares of the Company immediately following the first round of funding under a private offer of equity or debt securities; ● Common shares representing 5% of total number of outstanding common shares of the Company immediately following the commencement of clinical trials for Federal Drug Administration clearance of the product; and ● Common shares representing an adjustment to increase 7 to Stand’s total ownership to 19.99% of total number of outstanding common shares of the Company immediately following FDA clearance of the product for sale.

7.10%

Rights to issued

10,610,592